Get started
Author

Naruyasu Kakita

Observed names: N. Kakita, naruyasu kakita, カキタ, ナルヤス
ORCID: 0000-0002-2991-6456
Observed ORCID: 0000-0002-2991-6456
OpenAlex ID: A5070280648
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
2021 · Kazuhiro Kozumi, Takahiro Kodama, et al. · Hepatology · 173
PDF
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis
2012 · Tokuhiro Matsubara, Tatsuya Kanto, et al. · Hepatology · 144
Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus
2012 · Sachiyo Yoshio, Tatsuya Kanto, et al. · Hepatology · 110
PDF
Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll‐like receptors and retinoic acid inducible gene‐I
2008 · Masanori Miyazaki, Tatsuya Kanto, et al. · Journal of Medical Virology · 61
Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection
2012 · Koyo Higashitani, Tatsuya Kanto, et al. · Journal of Gastroenterology · 48
Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide
2011 · Mitsuru Sakakibara, Tatsuya Kanto, et al. · Cancer Immunology Immunotherapy · 43
Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis
2009 · I. Itose, T. Kanto, et al. · Journal of Viral Hepatitis · 33
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
2024 · Shusuke Kumazaki, Hayato Hikita, et al. · Alimentary Pharmacology & Therapeutics · 26
PDF
Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: A crucial role of CD25−FOXP3− T cells
2012 · Naruyasu Kakita, Tatsuya Kanto, et al. · International Journal of Cancer · 24
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD
2024 · Sadatsugu Sakane, Hayato Hikita, et al. · Hepatology Communications · 21
Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so‐called latency period of abnormal ammonia metabolism
2024 · Kazuhiro Katayama, Naruyasu Kakita · Hepatology Research · 19
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
2024 · Machiko Kai, Hayato Hikita, et al. · PLoS ONE · 17
PDF
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
2023 · Takayuki Matsumae, Takahiro Kodama, et al. · Cancers · 11
PDF
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients
2011 · Tatsuya Kanto, Michiyo Inoue, et al. · Journal of Gastroenterology · 10
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis
2022 · Kumiko Shirai, Hayato Hikita, et al. · PLoS ONE · 8
PDF
Zinc transporter 1 expression in hepatocellular carcinoma correlates with prognosis: A single-center retrospective study
2023 · Naruyasu Kakita, Kazuhiro Katayama, et al. · Journal of Trace Elements in Medicine and Biology · 7
PDF
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
2025 · Kazuki Maesaka, Hayato Hikita, et al. · Journal of Gastroenterology · 4
PDF
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
2025 · Kazuki Maesaka, Hayato Hikita, et al. · Journal of Gastroenterology and Hepatology · 3
PDF
[Hemobilia into a metallic biliary stent due to pseudoaneurysm: a case report].
2013 · Naoki Morishita, Tsutomu Nishida, et al. · PubMed · 3
[Advanced gastric cancer deriving from submucosal heterotopic gastric glands based on pathological diagnosis].
2013 · Dai Nakamatsu, Tsutomu Nishida, et al. · PubMed · 3
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
2026 · Chinatsu Nishioka, Yuki Tahata, et al. · PLoS ONE · 2
PDF
[Multidisciplinary treatment for metastasis in left perinephric space after the resection of left renal metastasis in a patient with hepatocellular carcinoma:a case report].
2024 · Shin Satake, Midori Jono, et al. · PubMed · 2
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2026 · Yu Sato, Takahiro Kodama, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study
2025 · Naruyasu Kakita, Midori Jono, et al. · Clinical Journal of Gastroenterology · 1
[A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
2014 · Yongkook Kim, Yohei Hosoda, et al. · PubMed · 1
Works count: 48
Citation count: 775
H-index: 12
I10-index: 14
Year
Topic
Type